The effort has being possible thanks to the strategic support and vision of the Bioprocess Development and Training Complex and the Puerto Rico Science Technology and Research Trust, who have supported CDI in the first phase of the project and are continuing to do so as the platform is optimized in a two year second phase that commenced in August 2009.

The company is offering Fast-MAb™ monoclonal antibody development services to companies and researchers. Companies that have presence in Puerto Rico qualify for tax incentives form the Commonwealth of Puerto Rico when they contract development services from CDI.

Very soon CDI will be inaugurating its proprietary products section. Here Fast-MAb™ - developed HighSpec™ - validated MAbs raised against important human proteins will be made available to researchers and institutions. To learn more about what makes a MAb HighSpec™, click here.